Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy
…, LM Lundgren, A Soni, N Ramchurren… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE Merkel cell carcinoma (MCC) is an aggressive skin cancer often caused by the
Merkel cell polyomavirus. Clinical trials of programmed cell death-1 pathway inhibitors for …
Merkel cell polyomavirus. Clinical trials of programmed cell death-1 pathway inhibitors for …
[HTML][HTML] Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma
…, RH Pierce, SP Fling, N Ramchurren… - Nature …, 2021 - nature.com
Cutaneous T cell lymphomas (CTCL) are rare but aggressive cancers without effective
treatments. While a subset of patients derive benefit from PD-1 blockade, there is a critically …
treatments. While a subset of patients derive benefit from PD-1 blockade, there is a critically …
[HTML][HTML] Pembrolizumab in relapsed and refractory mycosis fungoides and Sézary syndrome: a multicenter phase II study
…, L Sokol, SP Fling, N Ramchurren… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
… Fling, Nirasha Ramchurren, Steven M. Horwitz, Martin A. Cheever, Youn H. … Fling,
Nirasha Ramchurren, Asa Davis, Richard Shine, Shufeng Li, Sophia Fong, Jinah Kim, Yi …
Nirasha Ramchurren, Asa Davis, Richard Shine, Shufeng Li, Sophia Fong, Jinah Kim, Yi …
[HTML][HTML] Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab
…, NJ Miller, S Fling, L Lundgren, N Ramchurren… - … for immunotherapy of …, 2018 - Springer
Background We recently reported a 56% objective response rate in patients with advanced
Merkel cell carcinoma (MCC) receiving pembrolizumab. However, a biomarker predicting …
Merkel cell carcinoma (MCC) receiving pembrolizumab. However, a biomarker predicting …
[HTML][HTML] Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
…, C Church, T Akaike, N Ramchurren… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background Merkel cell carcinoma (MCC) is an aggressive skin cancer associated with
poor survival. Programmed cell death-1 (PD-1) pathway inhibitors have shown high rates of …
poor survival. Programmed cell death-1 (PD-1) pathway inhibitors have shown high rates of …
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets
…, T Keler, L Lundgren, C Morishima, N Ramchurren… - Nature cancer, 2020 - nature.com
Generating responses to tumor antigens poses a challenge for immunotherapy. This phase
II trial (NCT02129075) tested fms-like tyrosine kinase 3 (Flt3) ligand pre-treatment …
II trial (NCT02129075) tested fms-like tyrosine kinase 3 (Flt3) ligand pre-treatment …
Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses
…, AM Lacroix, L D'Amico, N Ramchurren… - Science translational …, 2022 - science.org
To uncover underlying mechanisms associated with failure of indoleamine 2,3-dioxygenase
1 (IDO1) blockade in clinical trials, we conducted a pilot, window-of-opportunity clinical …
1 (IDO1) blockade in clinical trials, we conducted a pilot, window-of-opportunity clinical …
[HTML][HTML] PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy
…, S Rulli, R Gottardo, N Ramchurren… - … for Immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background Clinical benefit from programmed cell death 1 receptor (PD-1) inhibitors relies
on reinvigoration of endogenous antitumor immunity. Nonetheless, robust immunological …
on reinvigoration of endogenous antitumor immunity. Nonetheless, robust immunological …
[HTML][HTML] IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer …
…, HT Maecker, C Duault, N Ramchurren… - … for ImmunoTherapy of …, 2021 - ncbi.nlm.nih.gov
Background Sipuleucel-T (sip-T) is a Food and Drug Administration (FDA)-approved
autologous cellular immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). …
autologous cellular immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). …
[HTML][HTML] Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy
…, SP Fling, R Kulikauskas, N Ramchurren… - … for immunotherapy of …, 2018 - Springer
Background Merkel cell carcinoma (MCC) is an aggressive skin cancer that frequently
responds to anti-PD-1 therapy. MCC is associated with sun exposure and, in 80% of cases, …
responds to anti-PD-1 therapy. MCC is associated with sun exposure and, in 80% of cases, …